Erbumine

N/A

Report date: 2026/03/30 20:02:02
NME

Base Information

Drug NameErbumine
Drug Alias NameAK-01LY-3295668
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerine/threonine-protein kinase Aurora-A inhibitors
TargetsSerine/threonine-protein kinase Aurora-A
Therapy Area/IndicationsMetastatic breast cancerSolid tumoursNeoplasm Metastasis +[16] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[12] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesEli Lilly And CompanyThe University Of Texas MD Anderson Cancer Center
Inactive CompaniesAurka Pharma Inc
Active IndicationsEndometrial NeoplasmsCarcinoma, Non-Small-Cell LungLung Neoplasms +[8] 
Inactive IndicationsMetastatic breast cancerSolid tumoursNeoplasm Metastasis +[8] 

Other Information

ATC CodeN/A
Related LinksN/A